BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Wednesday, 13 November 1996.
U.S. AUTOIMMUNE DISEASE THERAPEUTIC MARKETS reports that more than 20 million people are afflicted with rheumatoid arthritis, asthma, psoriasis, Type I diabetes, multiple sclerosis, asthma, lupus, Graves' and inflammatory bowel diseases, Sjogren's syndrome and scleroderma.
For reasons yet unknown, instead of attacking only viruses and bacteria that threaten health, the immune system malfunctions and also attacks and destroys healthy tissue; the effects of these disorders are devastating to sufferers, who spend money on therapies that relieve symptoms but do nothing about the underlying cause of the disorder.
"Assuming a conservative price of $1,000 per patient per year," said medical analyst Mitch Murakami, "the revenue potential of the eleven autoimmune diseases covered in this report is $20 billion per year."
That potential is inducing new companies to embark on the long, expensive process to develop drugs offering the relief so desperately sought by patients. The drug approval process in the United States can take an average of 12 years to complete and cost up to $250 million.
The financial payoff can be astounding. The Food and Drug Administration approved the first new treatments for autoimmune diseases in 1993. Berlex Laboratories' Betaseron and Sandoz Pharmaceutical's Sandimmune were approved for multiple sclerosis and psoriasis, respectively. These two compounds generated revenues approaching $300 million in 1995.
Over the next three years, several new autoimmune disease therapies could receive regulatory approval for commercial sale and generate more than $1 billion annually. Currently, compounds to treat multiple sclerosis, rheumatoid arthritis and psoriasis are all undergoing FDA regulatory review.
One of the more intriguing developments is bioartificial pancreases for Type I diabetics, which could be implanted into patients, replacing lost insulin-producing cells. If successful in human clinical trials, the bioartificial pancreas would eliminate the need for multiple daily insulin injections and prevent long-term medical problems associated with Type I diabetes -- blindness and vascular disease.
This study by Frost & Sullivan concludes: "The autoimmune disease therapeutic products market offers enormous opportunities to companies that have sound technology and can develop safe, effective new treatments for these debilitating diseases. Firms that can develop safer, more effective treatments could reap the rewards of hundreds of millions in annual sales."
It details in length how and why some companies stand to gain -- and some to lose -- market shares. Its analysis provides significant strategic insight into the direction and velocity of the autoimmune disease therapeutic market; companies receive recommendations for strategic action when purchasing this report, as well as a reliable source of continuing research by an international consulting firm dedicated to defining market problems, needs and opportunities.
Companies included in this research are: Abbott Laboratories, Agouron Pharmaceuticals, Inc., Allergan, Inc., Amgen, Inc., Amylin Pharmaceuticals, Anergen, Inc., Ares-Serono Group Serono Laboratories, Inc., ARIAD Pharmaceuticals, Inc., Athena Neurosciences, Inc., AutoImmune, Inc., Bayer, Inc., Berlex Laboratories, BetaGene, Biogen, Inc., BioHybrid Technologies, Inc., Boehringer Ingelheim Pharmaceutical, Inc., Bristol-Myers Squibb, Carrington Laboratories, Inc., Cell Genesys, Inc., Centocor, Inc., Ciba Pharmaceuticals, Inc., Cortech, Inc., Cytel Corporation, Dura Pharmaceuticals, Inc., Eli Lilly & Co., Ferndale Laboratories Co., Forest Laboratories, Inc., Fujisawa, U.S.A., Inc., Genentech, Inc., Genetics Institute, Inc., Geneva Pharmaceuticals, Inc., Glaxo- Wellcome, Inc., Hoechst-Roussell Pharmaceutical, ICN Pharmaceuticals, Inc., ICOS Corp., IDE Interstate, Inc., IDEC Pharmaceuticals Corp., ImmuLogic Pharmaceutical Corp., The Immune Response Corp., Immunex Corp., Isis Pharmaceuticals, Inc., Ivax Corp., Ixsys, Inc., La Jolla Pharmaceutical Co., Lederle Laboratories, Ligand Pharmaceuticals, Inc., Merck & Co., Inc., MGI PHARMA, INC., Monsanto Co., Mutual Pharmaceutical Co., Mylan Laboratories, Inc., Neocrin Co., Neurocrine Biosciences, Inc., Novo Nordisk Pharmaceuticals, Inc., Parke-Davis Group, Pfizer, Inc., Pharmaceutical Discovery Corp., Pharmacia and Upjohn, Inc., Procept, Inc., Protein Design Labs, Repligen Corp., Rhone-Poulenc Rorer Pharmaceuticals, Inc., Roche Bioscience, Royce Labs, Inc., Sandoz Pharmaceuticals Corp., Sanofi Winthrop Pharmaceuticals, Schering-Plough Laboratories, Searle & Co., Seragen, Inc., SmithKline Beecham Pharmaceuticals, T Cell Sciences, Inc., Teva Marion Partners, Vertex Pharmaceuticals, Inc., VivoRx, Inc., Westwood-Squibb Pharmaceuticals, Inc., Whitehall-Robbins Healthcare, W.R. Grace & Company, Wyeth-Ayerst, and Zeneca Pharmaceuticals.
Frost & Sullivan is an international marketing consulting company that monitors the biotech and pharmaceutical therapeutics industry for market trends, market measurements, and strategies. This ongoing research is utilized to update a series of research publications and to support industry participants with customized consulting needs. Free executive summaries of all Frost & Sullivan reports are available to the press.
Report: 5484-52 Publication Date: July 1996 Price: $2495
--30--cmf/sf*
CONTACT: Frost & Sullivan Russ Pecoraro, 415/961-9000 ext. 488 (California) rpecoraro@frost.com http://www.frost.com or Kristina Menzefricke, 44/171-730-3438 (London) Stefan Gerhardt, 49/69-235057 (Frankfurt)
REPEATS: New York 212-752-9600 or 800-221-2462; Boston 617-236-4266 or 800-225-2030; SF 415-986-4422 or 800-227-0845; LA 310-820-9473 Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: http://www.businesswire.com
Copyright (c) 1996/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
961113
BW961114
Copyright © 1996 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .